Introduction
============

Infections caused by *Staphylococcus aureus* have a poorer prognosis when the infecting strain is MRSA ([@b7-idr-1-057]). Since its first report in 1961 ([@b13-idr-1-057]), the strain has been progressively causing increased mortality, morbidity, and health care costs with skin and soft tissue infections, ventilator-associated pneumonia, catheter associated bacteremia, and many other infections in hospitals and communities. First detected in hospitals, methicillin resistance is now increasingly recognized in the community ([@b6-idr-1-057]).

In addition to dire consequences of infections, MRSA strains are important for their resistance to many other commonly used antibiotics and the emergence of resistance to vancomycin, the drug that has been used to treat MRSA infections for more than three decades. Thus, it is immensely important to study the antibiogram of MRSA in a given hospital so that the results of such studies can be exploited to minimize the irrational use of vancomycin when other antibiotics would cure an infection. Reports of emergence of vancomycin resistance in *S. aureus* from India ([@b4-idr-1-057]; [@b32-idr-1-057]; [@b26-idr-1-057]) further justify this necessity.

The prevalence of MRSA has varied from hospital to hospital in various countries. About 40% of *S. aureus* infections acquired in large US hospitals (500 or more beds) are methicillin-resistant ([@b25-idr-1-057]). Prevalence is constantly soaring in many countries, and in some hospitals, more than half of all *S. aureus* disease isolates are MRSA ([@b34-idr-1-057]). In many American and European hospitals, the percentage of MRSA has ranged from 29% to 35% of all clinical isolates. Meanwhile, information from developing countries is provided only by relatively sophisticated hospitals (Degerli et al 2000; Gastmeier et al 2000; [@b28-idr-1-057]); as a consequence, the data on MRSA prevalence, most of which are from developed countries, are inadequate in estimating the overall global distribution ([@b23-idr-1-057]; [@b33-idr-1-057]; [@b15-idr-1-057]; [@b31-idr-1-057]; [@b3-idr-1-057]; [@b17-idr-1-057]; [@b24-idr-1-057]; [@b16-idr-1-057]; [@b18-idr-1-057]).

The present study uncovers the prevalence of multidrug-resistant MRSA strains and investigates their antibiotic sensitivity pattern in a tertiary care hospital of northern India.

Material and methods
====================

During August 2002 and June 2006, a total of 783 strains of *S. aureus* were isolated from various specimens of different patients visiting and admitted at Sir Sundar Lal Hospital, a 972 bed tertiary care teaching hospital of Banaras Hindu University at Varanasi, India.

Isolation and identification of staphylococci from clinical specimens
---------------------------------------------------------------------

All specimens, except urine for which cystine lactose electrolyte deficient agar (HiMedia, New Delhi, India) was used, were cultured on blood agar and MacConkey agar (HiMedia, New Delhi, India). *S. aureus* was identified and differentiated from related organisms on the basis of colony morphology, Gram staining, catalase test, tube coagulase test using rabbit plasma, slidex staph plus (Biomerurix India Ltd, New Delhi, India), thermonuclease and acetoin production, and mannitol fermentation ([@b5-idr-1-057]). Using growth on blood agar, all the strains were subjected to the following tests. *S. aureus* ATCC 25923 (*mecA* negative) and ATCC 43300 (*mecA* positive) were used for the quality control of all the tests.

Disc diffusion test by Kirby--Bauer method
------------------------------------------

Mueller--Hinton agar (MHA) plates were overlaid with the saline suspension of a strain (turbidity matching 0.5 McFarland standard), and the following antibiotic discs procured from HiMedia, India were placed on the plate after 10 minutes, with six discs on a plate: penicillin (10 U), oxacillin (1 μg), gentamicin (10 μg), tobramycin (30 μg), amikacin (30 μg), netilmicin (30 μg), norfloxacin (10 μg), ciprofloxacin (5 μg), chloramphenicol (30 μg), erythromycin (15 μg), tetracycline (15 μg), trimethoprim/sulfamethoxazole (1.25/23.75 μg), nitrofurantoin (300 μg), vancomycin (30 μg), and sulbactam/cefoperazone (30/75 μg). After 24 and 48 h of incubation at 35 °C, the plates were read using the NCCLS break-points as reference ([@b20-idr-1-057]).

Oxacillin MIC test
------------------

Gradient plates of MHA containing 2% NaCl were prepared with doubling dilutions (from 0.25 μg/ml to 256 μg/ml) of oxacillin. Inoculum was prepared by diluting 0.5 McFarland equivalent suspension of a strain with sterile normal saline to the concentration of 10^4^ CFU/ml. The plates were spot-inoculated and incubated at 35 °C for 24 h. An oxacillin minimum inhibitory concentration (MIC) of ≤2 μg/ml indicated that the strain was susceptible and that of \>2 μg/ml resistant ([@b19-idr-1-057]).

The *mecA* gene detection by PCR
--------------------------------

Staphylococcal DNA was isolated using chloroform: phenol extraction method ([@b27-idr-1-057]). The primers used for detection of the *mecA* gene were MecA1 (5'-GTA GAA ATG ACT GAA CGT CCG ATA A) and MecA2 (5'-CCA ATT CCA CAT TGT TTC GGT CTA A), as described earlier ([@b10-idr-1-057]). A Biometra DNA thermocycler was programmed for initial denaturation at 94 °C for 4 min; 30 cycles of amplification (denaturation at 94 °C for 45 sec, annealing at 56 °C for 45 sec, and extension at 72 °C for 30 sec); and a final extension at 72 °C for 2 min. To visualize, 10 μl of the PCR amplicon was loaded in 2% agarose gel in TBE (0.089 M Tris, 0.089 M boric acid, 0.002 M EDTA) containing 0.5 μl/ml of ethidium bromide and visualized by using UV transillumination at 300 nm. DNA fragments of 310 bp corresponded to the *mecA* gene.

Results
=======

Of the 783 *S. aureus* strains (503 from outpatient departments \[OPDs\] and 280 from wards), 301 (38.44%) -- 187 from OPDs and 114 from wards -- showed methicillin resistance in disc diffusion and MIC tests and were confirmed as MRSA by the *mecA* gene PCR. The remaining 482 (61.56%) were MSSA. [Table 1](#t1-idr-1-057){ref-type="table"} shows the pattern of resistance shown by MRSA strains as well as compares its distribution in OPDs and wards. Resistance to penicillin was highest (97%) followed by cotrimoxazole (95.68%), chloramphenicol (92.36%), and norfloxacin (90.7%).

The resistance pattern of MRSA was somewhat varying between OPDs and wards for macrolides, chloramphenicol, tetracycline, cotrimoxazole, nitrofurantoin and betalactam/betalactamase inhibitor combination; the pattern was more or less same for other antibiotics ([Table 1](#t1-idr-1-057){ref-type="table"}).

Out of 301 MRSA isolates, 217 (72.1%) were multidrug resistant, with 136 being resistant to more than three antimicrobials except vancomycin. One MRSA strain was found to be resistant to all antibiotics including vancomycin ([Table 2](#t2-idr-1-057){ref-type="table"}).

Frequency of isolating MRSA was maximum in cutaneous and wound specimens (42.2%) followed by blood, respiratory specimens, and urine ([Table 3](#t3-idr-1-057){ref-type="table"}).

Discussion
==========

Studies show that the epidemiology of MRSA over different parts of India is not uniform. The present study reports 38.44% MRSA among *S. aureus* isolates, whereas an earlier study done in the same hospital here had shown a higher prevalence of 54.8% ([@b3-idr-1-057]). Some studies have reported comparable prevalence: 38.56% in Delhi ([@b17-idr-1-057]), 31.1% in a multicenter study in Tamilnadu ([@b24-idr-1-057]), and 39.50% in South Gujarat ([@b18-idr-1-057]). In contrast, other studies have reported entirely different prevalence: 24% in Vellore ([@b23-idr-1-057]), 80.89% in Indore ([@b33-idr-1-057]), 52.9% in Assam ([@b4-idr-1-057]), 19.56% in Nagpur ([@b31-idr-1-057]), and 24% in Chandhigarh ([@b16-idr-1-057]). Although it's extremely difficult to explain these conflicting data with regards to both time and place of study, the variation is probably due to differential clonal expansion and drug pressure in community.

Given the fact that staphylococci spread by direct or indirect person-to-person contact, the emergence of multidrug-resistant stains of MRSA is worrisome in the present therapeutic scenario. Multidrug resistance was defined as resistance of a MRSA strain towards three or more antibiotics at a given point of time. In the USA, some workers ([@b30-idr-1-057]) have reported multi-drug resistance rates of 67.8% (for inpatients) and 65% (for outpatients) in lower respiratory tract MRSA isolates. In Nigerian women, a total of 43 *S. aureus* out of 60 were found to be multidrug resistant ([@b21-idr-1-057]). We found a high percentage of multidrug-resistant MRSA (72.1%) in our hospital. If we look into the Indian literature, it seems the burden of multi drugresistant-MRSA is increasing over time: for instance, 23.2% was reported by [@b15-idr-1-057]; 32% by Anupurva and colleagues in 2003; and 63.6% by [@b24-idr-1-057]. The lesson is clear: MRSA surveillance and strict drug policy are of paramount importance, or else the threat will increase.

The MRSA strain that showed resistance to all antimicrobials including vancomycin was isolated from a 56-year-old male patient admitted in post-operative ward of our hospital. The zone of inhibition shown by this strain in response to vancomycin disc was less than 9 mm; therefore we tentatively characterized this strain as vancomycin resistant *S. aureus*. Molecular investigation of the strain for the presence of *vanA/B* gene is needed to clarify its exact status.

Patterns of resistance shown by MRSA to Beta-lactams, aminoglycosides and quinolones are more or less identical in OPDs and wards, while the same to erythromycin, chloramphenicol, tetracycline, cotrimoxazole, nitrofurantoin, and betalactam/betalactamase inhibitor combination present certain level of difference between their distributions in OPDs and wards. This is a reflection of differential drug pressure.

Currently, the majority (80%--90%) of *S. aureus* strains in communities are beta-lactamase producers hence resistant to penicillin and ampicillin ([@b22-idr-1-057]; [@b2-idr-1-057]). Recently more than 90% isolates from South Maharashtra have been found resistant to ampicillin, tobramycin, penicillin, erythromycin, kanamycin and gentamicin, whereas only 39.1% of strains are resistant to methicillin ([@b14-idr-1-057]). The choice is obviously oxacillin; however, fearing MRSA, clinicians may exploit vancomycin. Our study reports that antibiotics other than vancomycin -- for instance, amikacin, tobramycin, gentamicin, cefoperazone/sulbactam -- can be promising if a susceptibility testing is done, reserving vancomycin for life-threatening infections. A retrospective study of bacterial isolates from cases of neonatal septicemia over a period of five years from Chandigarh, India, has also reported that netilmicin was the most effective drug for *S. aureus* ([@b1-idr-1-057]).

Factors contributing to drug resistance in developing countries are myriad. Antibiotics are available without prescription at drug stores or even at general stores and injudiciously used in communities, animal husbandries, and fisheries. Traditional practitioners use allopathic drugs, and many practitioners who earn by selling medicines prescribe more drugs than necessary ([@b12-idr-1-057]). In a study from five districts of Tamilnadu, India, 285 general practitioners and specialists believed that antibiotics are over-prescribed: purulent discharge (65%), antibiotic-resistance concerns (48%), fever (40%), and patient satisfaction (29%) being the strong reasons for overprescription ([@b29-idr-1-057]). Poor quality antibiotics are produced at local levels, and patients show poor compliance to costly antimicrobials ([@b11-idr-1-057]). Therefore, there is no other way than to foil these malpractices, to constantly conduct microbiological surveillance like this, and follow infection control measures like hand washing and other aseptic techniques if we are to avoid therapeutic crisis resulting from multidrug-resistant MRSA.
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###### 

Resistance pattern of MRSA against various antimicrobials and its relative distribution in OPDs and wards

  **Antimicrobials**                                          **Overall resistance (n = 301)**   **Resistance in OPDs (n = 187)**   **Resistance in wards (n = 114)**
  ----------------------------------------------------------- ---------------------------------- ---------------------------------- -----------------------------------
  Penicillin                                                  97% (292)                          96.79% (181)                       97.37% (111)
  Gentamicin                                                  55.81% (168)                       55.6% (104)                        56.14% (64)
  Tobramycin                                                  53.49% (161)                       54.01% (101)                       52.63% (60)
  Amikacin                                                    41.53% (125)                       40.64% (76)                        42.98% (49)
  Netilmicin                                                  65.78% (198)                       65.24% (122)                       66.67% (76)
  Norfloxacin[^a^](#tfn2-idr-1-057){ref-type="table-fn"}      90.7% (273)                        90.91% (170)                       90.35% (103)
  Ciprofloxacin                                               75.75% (228)                       76.47% (143)                       75.56% (85)
  Chloramphenicol                                             92.36% (278)                       90.91% (170)                       94.74% (108)
  Erythromycin                                                68.77% (207)                       66.31% (124)                       72.81% (83)
  Tetracycline                                                76.1% (229)                        73.79% (138)                       79.82% (91)
  Trimethoprim/Sulphamethoxazole                              95.68% (288)                       94.12% (176)                       98.25% (112)
  Nitrofurantoin[^a^](#tfn2-idr-1-057){ref-type="table-fn"}   58.14% (175)                       60.43% (113)                       54.4% (62)
  Vancomycin                                                  0.33% (1)                          0%                                 0.88% (1)
  Cefoperazone/Sulbactam                                      65.12% (196)                       67.91% (127)                       60.53% (69)

**Note:**

Test done only for urine isolates.

**Abbreviations:** MRSA, methicillin-resistant *Staphylcoccus aureus*; OPD, outpatient departments.

###### 

Multidrug resistance[\*](#tfn5-idr-1-057){ref-type="table-fn"} in MRSA

  **Resistance to**                                                 **MRSA (n = 301)**
  ----------------------------------------------------------------- --------------------
  More than three nonvancomycin antimicrobials                      45.18% (136)
  All antimicrobials except vancomycin                              22.25% (67)
  All antimicrobials except vancomycin and cefoperazone/sulbactam   4.31% (13)
  All antimicrobials                                                0.033% (1)
  Total multidrug resistance                                        72.1% (217)

**Note:**

MRSA strains which were resistant to three or more than three antibiotics tested were considered to be multidrug-resistant MRSA.

**Abbreviation:** MRSA, methicillin-resistant *Staphylcoccus aureus*.

###### 

Frequency of *S. aureus* and MRSA in specimens

  **Clinical specimens**           ***S. aureus*(n = 783)**   **MRSA (n = 301)**
  -------------------------------- -------------------------- --------------------
  Pus and wound specimens          68.9% (540)                42.2% (228)
  Blood                            2.9% (23)                  34.8% (8)
  Respiratory specimens            3.3% (26)                  34.6% (9)
    Mid stream                     20.0 % (157)               26.7% (42)
    Catheterized                   2.4% (19)                  63.1% (12)
  Urine                                                       
    Bone aspirate                  1.0% (8)                   12.5% (1)
    CSF, ascetic fluid, EPF, HVS   1.3% (10)                  10% (1)

**Abbreviations:** CSF, cerebrospinal fluid; EPF, expressed prostatic fluid; HVS, high vaginal swab; MRSA, methicillin-resistant *Staphylcoccus aureus*.
